The FDA has approved a new indication for sunitinib (Sutent) to include the adjuvant treatment of renal cell carcinoma in patients at high risk of disease recurrence following nephrectomy.
Karen Singer
Advertisement
Articles by Karen Singer
Advertisement
Latest Updated Articles
FDA Approves Adjuvant Therapy for High-Risk Renal Cell CarcinomaPublished: November 17th 2017 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
2
Quarter Century Update: How can Partnerships Between Academia, Biotech, and Pharma be Better Structured?
3
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
4
